Trial Profile

Phase I Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surufatinib Combined With JS001 in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 28 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Surufatinib (Primary) ; Toripalimab (Primary)
Indications Adenocarcinoma; Carcinoma; Colorectal cancer; Gastric cancer; Neuroendocrine carcinoma; Neuroendocrine tumours; Oesophageal cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions

01 Feb 2023 Results (n=30) assessing the safety, preliminary efficacy, and pharmacokinetics of surufatinib, a small molecular tyrosine kinase inhibitor, combined with toripalimab, a programmed cell death protein-1 antibody, in patients with advanced solid tumors published in the Journal of Cancer Research and Clinical Oncology
28 Apr 2020 Interim results (n=30; Data cut off; 20 Jan 2020) presented at the 111th Annual Meeting of the American Association for Cancer Research - I
27 Mar 2019 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com